Gopakumar V Iyer

37PUBLICATIONS
333CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markersCancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (37)

|Oct 25, 2026
SLC25A28 is a synthetic lethal vulnerability in nucleotide excision repair-deficient cancers.

|Oct 23, 2026
Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial.

|Oct 20, 2026
Mutational Signatures and Hypermutation Phenotypes Define Bladder Cancers Arising in Waterpipe and Cigarette Smokers.

|Aug 27, 2026
A Phase 2 Basket Trial of Ado-Trastuzumab Emtansine for Patients with HER2 Amplified Cancers: A Non-Randomized Clinical Trial.

|Feb 27, 2026
A small-molecule inverse agonist of PPARγ for advanced solid tumors: a phase 1 trial.

Matthew D Galsky, Charlene Mantia, Michaela Bowden

|Feb 09, 2026
Urinary Biomarkers Objectively Measure Minimal Residual Disease in Non-Muscle-Invasive Bladder Cancer.

Andrew B Katims, Charlie White, Syed Muneeb Alam

Pageof 7

Frequent Collaborators

17 joint publications

David Solit

17 joint publications

Hikmat Al-Ahmadie

11 joint publications

Jonathan E Rosenberg

10 joint publications

Samuel Funt